A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

← catalyst calendar

NCT07643155 · readout in 172 d

Sponsored by Insmed Incorporated (industry) · INSM — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

30estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-14

actual

When the study began enrolling

Primary completion

2027-02-07

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-02-07

estimated

The whole study's end, after follow-up

First posted

2026-06-11

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Hepatic Impairment

Intervention

Drug: Treprostinil Palmitil Inhalation Powder — also filed as INS1009

Primary outcomes

what the primary-completion date above is the date OF

Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Treprostinil Palmitil (TP) and Treprostinil (TRE)